PARD (Poniard Pharmaceuticals) Cyclically Adjusted PB Ratio: (As of Jul. 09, 2026)


What is Poniard Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Poniard Pharmaceuticals  (OTCPK:PARD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Poniard Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Poniard Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Poniard Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Poniard Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2011 is calculated as:

For example, Poniard Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2011 was:

Adj_Book=Book Value per Share/CPI of Sep. 2011 (Change)*Current CPI (Sep. 2011)
=2.078/226.8890*226.8890
=2.078

Current CPI (Sep. 2011) = 226.8890.

Poniard Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200112 375.775 176.700 482.508
200203 308.495 178.800 391.466
200206 239.613 179.900 302.199
200209 133.321 181.000 167.122
200212 156.893 180.900 196.779
200303 120.277 184.200 148.152
200306 175.184 183.700 216.371
200309 150.569 185.200 184.462
200312 254.190 184.300 312.930
200403 269.584 187.400 326.391
200406 239.976 189.700 287.021
200409 200.357 189.900 239.383
200412 161.426 190.300 192.463
200503 135.839 193.300 159.443
200506 73.021 194.500 85.181
200509 50.937 198.800 58.134
200512 22.161 196.800 25.549
200603 1.684 199.800 1.912
200606 99.621 202.900 111.399
200609 91.486 202.900 102.302
200612 82.258 201.800 92.485
200703 45.634 205.352 50.420
200706 118.600 208.352 129.152
200709 111.813 208.490 121.680
200712 102.769 210.036 111.015
200803 94.062 213.528 99.948
200806 81.246 218.815 84.244
200809 69.161 218.783 71.723
200812 54.952 210.228 59.307
200903 41.310 212.709 44.064
200906 32.105 215.693 33.771
200909 23.208 215.969 24.381
200912 22.471 215.949 23.609
201003 18.302 217.631 19.081
201006 14.197 217.965 14.778
201009 10.043 218.439 10.431
201012 6.961 219.179 7.206
201103 6.317 223.467 6.414
201106 4.199 225.722 4.221
201109 2.078 226.889 2.078

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.